Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
Conditions
Brief summary
This study evaluates how well the heart, lungs, and muscles are working individually, and how these systems are working together in transplant survivors. Information collected in this study may help doctors to understand why hematopoietic stem cell transplant survivors are at higher risk for developing cardiovascular disease.
Detailed description
PRIMARY OBJECTIVES: I. Evaluate cardiovascular reserve capacity, as measured by peak oxygen consumption (VO2peak), in hematopoietic cell transplantation (HCT) survivors. II. Define the determinants of VO2peak impairment in HCT survivors. OUTLINE: Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.
Interventions
PROCEDUREBioelectric Impedance Analysis
Undergo bioelectric impedance analysis
PROCEDUREBiospecimen Collection
Undergo collection of blood samples
PROCEDURECardiopulmonary Exercise Testing
Undergo cardiopulmonary exercise test
PROCEDUREEchocardiography
Undergo echocardiogram
PROCEDUREPhysical Performance Testing
Undergo physical function tests
PROCEDUREPulmonary Function Test
Undergo pulmonary function test
OTHERQuestionnaire Administration
Ancillary studies
PROCEDUREUltrasound
Undergo musculoskeletal ultrasound
Sponsors
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
City of Hope Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age at HCT \>= 18 years * Diagnosis of acute leukemia (myeloid, lymphoid), lymphoma (non-Hodgkin, Hodgkin), multiple myeloma or myelodysplastic syndromes * Planning to undergo first autologous or allogeneic transplant * Able to fluently read and write in English * Able to understand and sign the study specific informed consent form (ICF) * Physically able and willing to complete all study procedures
Exclusion criteria
* Unstable bone lesions per electronic medical record review and/or notification from patient's primary physician * Unstable angina or history of acute myocardial Infarction (\< 5 days of any planned study procedures) * Recurrent syncope * Acute myocarditis or pericarditis * Symptomatic severe aortic stenosis * Uncontrolled arrhythmia causing symptoms * Pulmonary embolus \< 3 month of study procedures * Thrombosis of lower extremities * Moderate or severe persistent asthma (National Asthma Education & Prevention) * Room air desaturation at rest =\< 85% * Non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis) * Anemia (hemoglobin \[Hgb\] \< 8 g/dL)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular reserve capacity, as measured by VO2peak, in HCT survivors | Up to 24 months post-hematopoietic cell transplantation (HCT) | We will measure initial VO2peak in patients prior to HCT and its post-HCT trajectory over time; compare VO2peak in HCT survivors at baseline (pre-HCT), 6m, 1Y, and 2Y post-HCT to established age- and sex-normative data; and define the association between VO2peak and self-reported health-related quality of life (HRQOL) at baseline/over time. |
| Determinants of VO2peak impairment in HCT survivors | Up to 24 months post-hematopoietic cell transplantation (HCT) | We will use Generalized Estimating Equation(GEE) and generalized linear models to examine the correlation between VO2peak and measures of: 1. cardiac (left ventricular function/ contractility \[systolic, diastolic, cardiac output, strain\], ventricular-arterial (VA) coupling, arterial elastance); 2. pulmonary (obstructive, restrictive lung disease, diffusion capacity); 3. musculoskeletal (body composition \[% lean muscle mass\], muscle quality, two minute step in place test, 30 second sit to stand test, timed up and go); and 4. hematologic function, adjusting for potential confounding variables (e.g. age, sex) and time since HCT. |
Countries
United States
Outcome results
None listed